National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia; and
Department of Immunization, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland.
Pediatrics. 2016 Mar;137(3):e20153741. doi: 10.1542/peds.2015-3741. Epub 2016 Feb 16.
Several varicella vaccines are available worldwide. Countries with a varicella vaccination program use 1- or 2-dose schedules.
We examined postlicensure estimates of varicella vaccine effectiveness (VE) among healthy children.
Systematic review and descriptive and meta-analysis of Medline, Embase, Cochrane libraries, and CINAHL databases for reports published during 1995-2014.
Publications that reported original data on dose-specific varicella VE among immunocompetent children.
We used random effects meta-analysis models to obtain pooled one dose VE estimates by disease severity (all varicella and moderate/severe varicella). Within each severity category, we assessed pooled VE by vaccine and by study design. We used descriptive statistics to summarize 1-dose VE against severe disease. For 2-dose VE, we calculated pooled estimates against all varicella and by study design.
The pooled 1-dose VE was 81% (95% confidence interval [CI]: 78%-84%) against all varicella and 98% (95% CI: 97%-99%) against moderate/severe varicella with no significant association between VE and vaccine type or study design (P > .1). For 1 dose, median VE for prevention of severe disease was 100% (mean = 99.4%). The pooled 2-dose VE against all varicella was 92% (95% CI: 88%-95%), with similar estimates by study design.
VE was assessed primarily during outbreak investigations and using clinically diagnosed varicella.
One dose of varicella vaccine was moderately effective in preventing all varicella and highly effective in preventing moderate/severe varicella, with no differences by vaccine. The second dose adds improved protection against all varicella.
全球有多种水痘疫苗可供使用。实施水痘疫苗接种计划的国家采用 1 剂或 2 剂方案。
我们研究了上市后水痘疫苗效力(VE)在健康儿童中的估计值。
对 1995 年至 2014 年期间发表的 Medline、Embase、Cochrane 图书馆和 CINAHL 数据库中的系统评价和描述性及荟萃分析进行了系统性评价。
报告了免疫功能正常儿童中剂量特异性水痘 VE 的原始数据的出版物。
我们使用随机效应荟萃分析模型,根据疾病严重程度(所有水痘和中度/重度水痘)获得了单剂量 VE 的汇总估计值。在每个严重程度类别中,我们评估了疫苗和研究设计对汇总 VE 的影响。我们使用描述性统计数据总结了针对严重疾病的 1 剂 VE。对于 2 剂 VE,我们计算了针对所有水痘和研究设计的汇总估计值。
1 剂 VE 对所有水痘的汇总估计值为 81%(95%置信区间[CI]:78%-84%),对中度/重度水痘的汇总估计值为 98%(95%CI:97%-99%),与疫苗类型或研究设计之间无显著关联(P>.1)。对于 1 剂,预防严重疾病的 VE 中位数为 100%(均值=99.4%)。2 剂 VE 对所有水痘的汇总估计值为 92%(95%CI:88%-95%),不同研究设计的估计值相似。
VE 主要在暴发调查期间并使用临床诊断的水痘进行评估。
1 剂水痘疫苗对预防所有水痘具有中等效力,对预防中度/重度水痘具有高度效力,且疫苗之间无差异。第二剂可提高对所有水痘的保护效果。